A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

Phase 2 Completed 399 enrolled Medigen Vaccine Biologics Corp.

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine compared to placebo in participants aged ≥ 12 to \< 18 years.

Timeline

Start: 2021-07-22
Primary completion: 2021-10-25
Completion: 2022-03-21

Publications

Liu LT, Chiu CH, Chiu NC, Tan BF, Lin CY, Cheng HY, Lin MY, Lien CE, Chen C, Huang LM. Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial. NPJ Vaccines. 2022 Dec 16;7(1):165. doi: 10.1038/s41541-022-00589-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVC-COV1901	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.